Dalpiciclib
- Generic Name
- Dalpiciclib
- Drug Type
- Small Molecule
- Chemical Formula
- C25H30N6O2
- CAS Number
- 1637781-04-4
- Unique Ingredient Identifier
- 5ZHA5P4PFX
Dalpiciclib Plus Letrozole Shows Promise in Phase II Trial for HR+/HER2- Breast Cancer
• A phase II trial demonstrated that combining dalpiciclib with letrozole achieved a 55.2% objective response rate in postmenopausal women with HR+/HER2- breast cancer, showing significant antitumor activity.
• The treatment led to substantial reduction in Ki-67 expression from 17.5% to 1.8% after two weeks, with 75% of patients achieving complete cell cycle arrest.
• Novel predictive biomarkers TFRC, SCUBE2, and MMP11A were identified through gene expression analysis, potentially enabling better patient selection for neoadjuvant therapy.
Lerociclib Plus Fulvestrant Shows Promise in HR+/HER2- Advanced Breast Cancer
• The LEONARDA-1 phase 3 trial demonstrated that lerociclib plus fulvestrant significantly improved progression-free survival (PFS) compared to placebo plus fulvestrant in patients with HR+/HER2- advanced breast cancer.
• The combination of lerociclib and fulvestrant showed a manageable safety profile, with hematological toxicities being the most common adverse events, effectively managed with dose adjustments.
• Lerociclib plus fulvestrant exhibited efficacy across various patient subgroups, including those with primary endocrine therapy resistance and liver metastasis, addressing a critical unmet need.
• The study supports lerociclib plus fulvestrant as a potential treatment option for patients with HR+/HER2- advanced breast cancer who have progressed on prior endocrine therapy.
Histone Deacetylase Inhibitors Show Promise in Breast Cancer Clinical Trials
• Clinical trials evaluating histone deacetylase (HDAC) inhibitors in breast cancer (BRCA) are underway across 24 regions, with the United States and China leading the efforts.
• The majority of these trials are in early phases (Phase I and II), with Chidamide being the most investigated HDAC inhibitor in BRCA clinical trials.
• Combination therapies involving HDAC inhibitors with hormone therapy, immunotherapy, and targeted therapy are being explored to improve outcomes in BRCA.
• Further research into the mechanisms of HDAC inhibitors is essential to optimize their integration into BRCA treatment strategies and overcome resistance.
SABCS 2024 Highlights Advances in Breast Cancer Treatment
The SABCS 2024 conference showcased significant advancements in breast cancer treatment, including promising results from clinical trials of new therapies like SIM0270 and Imlunestrant, insights into racial disparities in treatment outcomes, and the potential of liquid biopsies and AI in healthcare.
Real-World Study Affirms Palbociclib's Efficacy in Chinese HR+/HER2- Metastatic Breast Cancer Patients
• A real-world study in Northwest China confirms Palbociclib plus endocrine therapy (ET) benefits HR+/HER2- metastatic breast cancer (MBC) patients, aligning with global findings.
• The study highlights that earlier initiation of Palbociclib shows better outcomes, with median PFS of 14.2 months in the first-line setting.
• Poorer prognosis was observed in patients with prior chemotherapy, low progesterone receptor (PgR) expression, and more than three metastatic sites.
• The research suggests Palbociclib-based therapy is a viable option for MBC patients in China, even in later lines of therapy, despite economic and healthcare system limitations.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath